Focal segmental glomerulosclerosis (FSGS) is a histological pattern of glomerular injury, rather than a single disease, that is caused by diverse clinicopathological entities with different mechanisms of injury with the podocyte as the principal target of lesion, leading to the characteristic sclerotic lesions in parts (i.e., focal) of some (i.e., segmental) glomeruli. The lesion of FSGS has shown an increasing prevalence over the past few decades and is considered the most common glomerular cause leading to ESKD. Primary FSGS, which usually presents with nephrotic syndrome, is thought to be caused by circulating permeability factors that have a main role in podocyte foot process effacement. Secondary forms of FSGS include maladaptive FSGS secondary to glomerular hyperfiltration such as in obesity or in cases of loss in nephron mass, virus-associated FSGS, and drug-associated FSGS that can result in direct podocyte injury. Genetic FSGS is increasingly been recognized and a careful evaluation of patients with atypical primary or secondary FSGS should be performed to exclude genetic causes. Unlike primary FSGS, secondary and genetic forms of FSGS do not respond to immunosuppression and tend not to recur after kidney transplantation. Distinguishing primary FSGS from secondary and genetic causes has a prognostic significance and is crucial for an appropriate management. In this review, we examine the pathogenesis, clinical approach to distinguish between the different causes, and current recommendations in the management of FSGS.

1.
Rydel
JJ
,
Korbet
SM
,
Borok
RZ
,
Schwartz
MM
.
Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment
.
Am J Kidney Dis
.
1995 Apr
;
25
(
4
):
534
42
.
2.
Schwartz
MM
,
Korbet
SM
.
Primary focal segmental glomerulosclerosis: pathology, histological variants, and pathogenesis
.
Am J Kidney Dis
.
1993 Dec
;
22
(
6
):
874
83
.
3.
De Vriese
AS
,
Sethi
S
,
Nath
KA
,
Glassock
RJ
,
Fervenza
FC
.
Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach
.
J Am Soc Nephrol
.
2018
;
29
(
3
):
759
74
.
4.
Rood
IM
,
Deegens
JK
,
Wetzels
JF
.
Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice
.
Nephrol Dial Transplant
.
2012 Mar
;
27
(
3
):
882
90
.
5.
Sim
JJ
,
Batech
M
,
Hever
A
,
Harrison
TN
,
Avelar
T
,
Kanter
MH
, et al.
Distribution of biopsy-proven presumed primary glomerulonephropathies in 2000–2011 among a racially and ethnically diverse US population
.
Am J Kidney Dis
.
2016 Oct
;
68
(
4
):
533
44
.
6.
Kitiyakara
C
,
Kopp
JB
,
Eggers
P
.
Trends in the epidemiology of focal segmental glomerulosclerosis
.
Semin Nephrol
.
2003 Mar
;
23
(
2
):
172
82
.
7.
Parsa
A
,
Kao
WH
,
Xie
D
,
Astor
BC
,
Li
M
,
Hsu
CY
, et al.
APOL1 risk variants, race, and progression of chronic kidney disease
.
N Engl J Med
.
2013 Dec 5
;
369
(
23
):
2183
96
.
8.
Hommos
MS
,
De Vriese
AS
,
Alexander
MP
,
Sethi
S
,
Vaughan
L
,
Zand
L
, et al.
The incidence of primary vs secondary focal segmental glomerulosclerosis: a clinicopathologic study
.
Mayo Clin Proc
.
2017 Dec
;
92
(
12
):
1772
81
.
9.
Kriz
W
,
Elger
M
,
Nagata
M
,
Kretzler
M
,
Uiker
S
,
Koeppen-Hageman
I
, et al.
The role of podocytes in the development of glomerular sclerosis
.
Kidney Int Suppl
.
1994 Feb
;
45
:
S64
72
.
10.
Kriz
W
,
Endlich
K
.
Hypertrophy of podocytes: a mechanism to cope with increased glomerular capillary pressures?
Kidney Int
.
2005 Jan
;
67
(
1
):
373
4
.
11.
Sethi
S
,
Glassock
RJ
,
Fervenza
FC
.
Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist
.
Nephrol Dial Transplant
.
2015 Mar
;
30
(
3
):
375
84
.
12.
Königshausen
E
,
Sellin
L
.
Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates
.
Biomed Res Int
.
2016
;
2016
:
3765608
.
13.
Canaud
G
,
Dion
D
,
Zuber
J
,
Gubler
MC
,
Sberro
R
,
Thervet
E
, et al.
Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS)
.
Nephrol Dial Transplant
.
2010 Apr
;
25
(
4
):
1321
8
.
14.
Gallon
L
,
Leventhal
J
,
Skaro
A
,
Kanwar
Y
,
Alvarado
A
.
Resolution of recurrent focal segmental glomerulosclerosis after retransplantation
.
N Engl J Med
.
2012 Apr 26
;
366
(
17
):
1648
9
.
15.
Wei
C
,
Trachtman
H
,
Li
J
,
Dong
C
,
Friedman
AL
,
Gassman
JJ
, et al.
Circulating suPAR in two cohorts of primary FSGS
.
J Am Soc Nephrol
.
2012 Dec
;
23
(
12
):
2051
9
.
16.
Reiser
J
,
Nast
CC
,
Alachkar
N
.
Permeability factors in focal and segmental glomerulosclerosis
.
Adv Chronic Kidney Dis
.
2014 Sep
;
21
(
5
):
417
21
.
17.
Rennke
HG
,
Klein
PS
.
Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis
.
Am J Kidney Dis
.
1989 Jun
;
13
(
6
):
443
56
.
18.
Kriz
W
,
Lemley
KV
.
A potential role for mechanical forces in the detachment of podocytes and the progression of CKD
.
J Am Soc Nephrol
.
2015 Feb
;
26
(
2
):
258
69
.
19.
Rosenberg
AZ
,
Kopp
JB
.
Focal segmental glomerulosclerosis
.
Clin J Am Soc Nephrol
.
2017 Mar 7
;
12
(
3
):
502
17
.
20.
Chen
P
,
Chen
BK
,
Mosoian
A
,
Hays
T
,
Ross
MJ
,
Klotman
PE
, et al.
Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells
.
J Am Soc Nephrol
.
2011 Mar
;
22
(
3
):
496
507
.
21.
Moudgil
A
,
Nast
CC
,
Bagga
A
,
Wei
L
,
Nurmamet
A
,
Cohen
AH
, et al.
Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy
.
Kidney Int
.
2001 Jun
;
59
(
6
):
2126
33
.
22.
Markowitz
GS
,
Appel
GB
,
Fine
PL
,
Fenves
AZ
,
Loon
NR
,
Jagannath
S
, et al.
Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate
.
J Am Soc Nephrol
.
2001 Jun
;
12
(
6
):
1164
72
.
23.
Markowitz
GS
,
Nasr
SH
,
Stokes
MB
,
D'Agati
VD
.
Treatment with IFN-α, -β, or -γ is associated with collapsing focal segmental glomerulosclerosis
.
Clin J Am Soc Nephrol
.
2010 Apr
;
5
(
4
):
607
15
.
24.
Herlitz
LC
,
Markowitz
GS
,
Farris
AB
,
Schwimmer
JA
,
Stokes
MB
,
Kunis
C
, et al.
Development of focal segmental glomerulosclerosis after anabolic steroid abuse
.
J Am Soc Nephrol
.
2010 Jan
;
21
(
1
):
163
72
.
25.
Santín
S
,
Bullich
G
,
Tazón-Vega
B
,
García-Maset
R
,
Giménez
I
,
Silva
I
, et al.
Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome
.
Clin J Am Soc Nephrol
.
2011 May
;
6
(
5
):
1139
48
.
26.
Patrakka
J
,
Kestilä
M
,
Wartiovaara
J
,
Ruotsalainen
V
,
Tissari
P
,
Lenkkeri
U
, et al.
Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients
.
Kidney Int
.
2000 Sep
;
58
(
3
):
972
80
.
27.
Choi
HJ
,
Lee
BH
,
Cho
HY
,
Moon
KC
,
Ha
IS
,
Nagata
M
, et al.
Familial focal segmental glomerulosclerosis associated with an ACTN4 mutation and paternal germline mosaicism
.
Am J Kidney Dis
.
2008 May
;
51
(
5
):
834
8
.
28.
Lepori
N
,
Zand
L
,
Sethi
S
,
Fernandez-Juarez
G
,
Fervenza
FC
.
Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults
.
Clin Kidney J
.
2018 Apr
;
11
(
2
):
179
90
.
29.
Eggers
PW
,
Kimmel
PL
.
Is there an epidemic of HIV Infection in the US ESRD program?
J Am Soc Nephrol
.
2004 Sep
;
15
(
9
):
2477
85
.
30.
Tzur
S
,
Rosset
S
,
Shemer
R
,
Yudkovsky
G
,
Selig
S
,
Tarekegn
A
, et al.
Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene
.
Hum Genet
.
2010 Sep
;
128
(
3
):
345
50
.
31.
Genovese
G
,
Tonna
SJ
,
Knob
AU
,
Appel
GB
,
Katz
A
,
Bernhardy
AJ
, et al.
A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9
.
Kidney Int
.
2010 Oct
;
78
(
7
):
698
704
.
32.
Kopp
JB
,
Nelson
GW
,
Sampath
K
,
Johnson
RC
,
Genovese
G
,
An
P
, et al.
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy
.
J Am Soc Nephrol
.
2011 Nov
;
22
(
11
):
2129
37
.
33.
Kopp
JB
,
Winkler
CA
,
Zhao
X
,
Radeva
MK
,
Gassman
JJ
,
D'Agati
VD
, et al.
Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS clinical trial
.
J Am Soc Nephrol
.
2015 Jun
;
26
(
6
):
1443
8
.
34.
Freedman
BI
,
Langefeld
CD
.
The new era of APOL1-associated glomerulosclerosis
.
Nephrol Dial Transplant
.
2012 Apr
;
27
(
4
):
1288
91
.
35.
Snoek
R
,
Nguyen
TQ
,
van der Zwaag
B
,
van Zuilen
AD
,
Kruis
HME
,
van Gils-Verrij
LA
, et al.
Importance of genetic diagnostics in adult-onset focal segmental glomerulosclerosis
.
Nephron
.
2019
;
142
(
4
):
351
8
.
36.
Landini
S
,
Mazzinghi
B
,
Becherucci
F
,
Allinovi
M
,
Provenzano
A
,
Palazzo
V
, et al.
Reverse phenotyping after whole-exome sequencing in steroid-resistant nephrotic syndrome
.
Clin J Am Soc Nephrol
.
2020 Jan 7
;
15
(
1
):
89
100
.
37.
Stokes
MB
,
D’Agati
VD
.
Morphologic variants of focal segmental glomerulosclerosis and their significance
.
Adv Chronic Kidney Dis
.
2014 Sep
;
21
(
5
):
400
7
.
38.
Schachter
AD
.
Computational simulation of renal biopsy accuracy in focal segmental glomerulosclerosis
.
Pediatr Nephrol
.
2006 Jul
;
21
(
7
):
953
7
.
39.
Francis
A
,
Trnka
P
,
McTaggart
SJ
.
Long-term outcome of kidney transplantation in recipients with focal segmental glomerulosclerosis
.
Clin J Am Soc Nephrol
.
2016 Nov 7
;
11
(
11
):
2041
6
.
40.
Ponticelli
C
.
Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation
.
Nephrol Dial Transplant
.
2010 Jan
;
25
(
1
):
25
31
.
41.
Maas
RJ
,
Deegens
JK
,
van den Brand
JA
,
Cornelissen
EA
,
Wetzels
JF
.
A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation
.
BMC Nephrol
.
2013 Feb 22
;
14
:
47
.
42.
Ding
WY
,
Koziell
A
,
McCarthy
HJ
,
Bierzynska
A
,
Bhagavatula
MK
,
Dudley
JA
, et al.
Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence
.
J Am Soc Nephrol
.
2014 Jun
;
25
(
6
):
1342
8
.
43.
Campise
M
,
Favi
E
,
Messa
P
.
Clinical outcomes of prophylactic and therapeutic plasmapheresis in adult deceased-donor kidney transplant recipients with primary focal segmental glomerulosclerosis
.
Exp Clin Transplant
.
2019 Aug
;
17
(
4
):
461
9
.
Available from
: http://www.ectrx.org/detail/archive/2019/17/4/0/461/0.
44.
Auñón
P
,
Polanco
N
,
Pérez-Sáez
MJ
,
Rodrigo
E
,
Sancho
A
,
Pascual
J
, et al.
Pre-emptive rituximab in focal and segmental glomerulosclerosis patients at risk of recurrence after kidney transplantation
.
Clin Kidney J
.
2019 Oct 3
;
sfz120
.
45.
Chailimpamontree
W
,
Dmitrienko
S
,
Li
G
,
Balshaw
R
,
Magil
A
,
Shapiro
RJ
, et al.
Probability, predictors, and prognosis of posttransplantation glomerulonephritis
.
J Am Soc Nephrol
.
2009 Apr
;
20
(
4
):
843
51
.
46.
Ponticelli
C
,
Moroni
G
,
Glassock
RJ
.
De Novo glomerular diseases after renal transplantation
.
Clin J Am Soc Nephrol
.
2014 Aug 7
;
9
(
8
):
1479
87
.
47.
Letavernier
E
,
Bruneval
P
,
Vandermeersch
S
,
Perez
J
,
Mandet
C
,
Belair
MF
, et al.
Sirolimus interacts with pathways essential for podocyte integrity
.
Nephrol Dial Transplant
.
2009 Feb
;
24
(
2
):
630
8
.
48.
Cosio
FG
,
Frankel
WL
,
Pelletier
RP
,
Pesavento
TE
,
Henry
ML
,
Ferguson
RM
.
Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: implications for graft survival
.
Am J Kidney Dis
.
1999 Oct
;
34
(
4
):
731
8
.
49.
Shen
WW
,
Chen
HM
,
Chen
H
,
Xu
F
,
Li
LS
,
Liu
ZH
.
Obesity-related glomerulopathy: body mass index and proteinuria
.
Clin J Am Soc Nephrol
.
2010 Aug
;
5
(
8
):
1401
9
.
50.
Korbet
SM
.
Treatment of primary FSGS in adults
.
J Am Soc Nephrol
.
2012 Nov
;
23
(
11
):
1769
76
.
51.
Fornoni
A
,
Sageshima
J
,
Wei
C
,
Merscher-Gomez
S
,
Aguillon-Prada
R
,
Jauregui
AN
, et al.
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis
.
Sci Transl Med
.
2011 Jun 1
;
3
(
85
):
85ra46
.
52.
Faul
C
,
Donnelly
M
,
Merscher-Gomez
S
,
Chang
YH
,
Franz
S
,
Delfgaauw
J
, et al.
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A
.
Nat Med
.
2008 Sep
;
14
(
9
):
931
8
.
53.
Glassock
RJ
.
Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum
.
J Am Soc Nephrol
.
2007 Aug
;
18
(
8
):
2221
5
.
54.
Fernandez-Juarez
G
,
Villacorta
J
,
Ruiz-Roso
G
,
Panizo
N
,
Martinez-Marín
I
,
Marco
H
, et al.
Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis
.
Clin Kidney J
.
2016 Jun
;
9
(
3
):
381
6
.
55.
Cattran
DC
,
Rao
P
.
Long-term outcome in children and adults with classic focal segmental glomerulosclerosis
.
Am J Kidney Dis
.
1998 Jul
;
32
(
1
):
72
9
.
56.
Stirling
CM
,
Mathieson
P
,
Boulton-Jones
JM
,
Feehally
J
,
Jayne
D
,
Murray
HM
, et al.
Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units
.
QJM
.
2005 Jun
;
98
(
6
):
443
9
.
57.
Ponticelli
C
,
Villa
M
,
Banfi
G
,
Cesana
B
,
Pozzi
C
,
Pani
A
, et al.
Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?
Am J Kidney Dis
.
1999 Oct
;
34
(
4
):
618
25
.
58.
Nagai
R
,
Cattran
DC
,
Pei
Y
.
Steroid therapy and prognosis of focal segmental glomerulosclerosis in the elderly
.
Clin Nephrol
.
1994 Jul
;
42
(
1
):
18
21
.
59.
Goumenos
DS
,
Tsagalis
G
,
El Nahas
AM
,
Shortland
JR
,
Davlouros
P
,
Vlachojannis
JG
, et al.
Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study
.
Nephron Clin Pract
.
2006
;
104
(
2
):
c75
82
.
60.
Laurin
LP
,
Gasim
AM
,
Poulton
CJ
,
Hogan
SL
,
Jennette
JC
,
Falk
RJ
, et al.
Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS
.
Clin J Am Soc Nephrol
.
2016 Mar 7
;
11
(
3
):
386
94
.
61.
Senthil Nayagam
L
,
Ganguli
A
,
Rathi
M
,
Kohli
HS
,
Gupta
KL
,
Joshi
K
, et al.
Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study
.
Nephrol Dial Transplant
.
2008 Jun
;
23
(
6
):
1926
30
.
62.
Troyanov
S
,
Wall
CA
,
Miller
JA
,
Scholey
JW
,
Cattran
DC
.
Focal and segmental glomerulosclerosis: definition and relevance of a partial remission
.
J Am Soc Nephrol
.
2005 Apr
;
16
(
4
):
1061
8
.
63.
Ponticelli
C
,
Rizzoni
G
,
Edefonti
A
,
Altieri
P
,
Rivolta
E
,
Rinaldi
S
, et al.
A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome
.
Kidney Int
.
1993 Jun
;
43
(
6
):
1377
84
.
64.
Cattran
DC
,
Appel
GB
,
Hebert
LA
,
Hunsicker
LG
,
Pohl
MA
,
Hoy
WE
, et al.
A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America nephrotic syndrome study group
.
Kidney Int
.
1999 Dec
;
56
(
6
):
2220
6
.
65.
Hodson
EM
,
Wong
SC
,
Willis
NS
,
Craig
JC
.
Interventions for idiopathic steroid-resistant nephrotic syndrome in children
.
Cochrane Database Syst Rev
.
2019 Nov 21
;
10
(
11
):
CD003594
.
66.
Gipson
DS
,
Trachtman
H
,
Kaskel
FJ
,
Greene
TH
,
Radeva
MK
,
Gassman
JJ
, et al.
Clinical trial of focal segmental glomerulosclerosis in children and young adults
.
Kidney Int
.
2011 Oct
;
80
(
8
):
868
78
.
67.
Cattran
DC
,
Wang
MM
,
Appel
G
,
Matalon
A
,
Briggs
W
.
Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis
.
Clin Nephrol
.
2004 Dec
;
62
(
6
):
405
11
.
68.
Segarra
A
,
Amoedo
ML
,
Martinez Garcia
JM
,
Pons
S
,
Praga
M
,
Garcia
EI
, et al.
Efficacy and safety of “rescue therapy” with mycophenolate mofetil in resistant primary glomerulonephritis: a multicenter study
.
Nephrol Dial Transplant
.
2007 May
;
22
(
5
):
1351
60
.
69.
Fernandez-Fresnedo
G
,
Segarra
A
,
González
E
,
Alexandru
S
,
Delgado
R
,
Ramos
N
, et al.
Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis
.
Clin J Am Soc Nephrol
.
2009 Aug
;
4
(
8
):
1317
23
.
70.
Kamei
K
,
Ishikura
K
,
Sako
M
,
Ito
S
,
Nozu
K
,
Iijima
K
.
Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children
.
Pediatr Nephrol
.
2020 Jan
;
35
(
1
):
17
24
.
71.
Heering
P
,
Braun
N
,
Müllejans
R
,
Ivens
K
,
Zäuner
I
,
Fünfstück
R
, et al.
Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis
.
Am J Kidney Dis
.
2004 Jan
;
43
(
1
):
10
8
.
72.
Sadowski
CE
,
Lovric
S
,
Ashraf
S
,
Pabst
WL
,
Gee
HY
,
Kohl
S
, et al.
A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome
.
J Am Soc Nephrol
.
2015 Jun
;
26
(
6
):
1279
89
.
73.
Ponticelli
C
,
Edefonti
A
,
Ghio
L
,
Rizzoni
G
,
Rinaldi
S
,
Gusmano
R
, et al.
Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial
.
Nephrol Dial Transplant
.
1993
;
8
(
12
):
1326
32
.
74.
Kronbichler
A
,
Kerschbaum
J
,
Fernandez-Fresnedo
G
,
Hoxha
E
,
Kurschat
CE
,
Busch
M
, et al.
Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review
.
Am J Nephrol
.
2019 Oct 3
;
39
(
4
):
322
30
.
75.
Ochi
A
,
Takei
T
,
Nakayama
K
,
Iwasaki
C
,
Kamei
D
,
Tsuruta
Y
, et al.
Rituximab treatment for adult patients with focal segmental glomerulosclerosis
.
Intern Med
.
2012
;
51
(
7
):
759
62
.
76.
Ruggenenti
P
,
Ruggiero
B
,
Cravedi
P
,
Vivarelli
M
,
Massella
L
,
Marasà
M
, et al.
Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome
.
J Am Soc Nephrol
.
2014 Apr
;
25
(
4
):
850
63
.
77.
Basu
B
.
Ofatumumab for rituximab-resistant nephrotic syndrome
.
N Engl J Med
.
2014 Mar 27
;
370
(
13
):
1268
70
.
78.
Hogan
J
,
Bomback
AS
,
Mehta
K
,
Canetta
PA
,
Rao
MK
,
Appel
GB
, et al.
Treatment of idiopathic FSGS with adrenocorticotropic hormone gel
.
Clin J Am Soc Nephrol
.
2013 Dec
;
8
(
12
):
2072
81
.
79.
Yu
CC
,
Fornoni
A
,
Weins
A
,
Hakroush
S
,
Maiguel
D
,
Sageshima
J
, et al.
Abatacept in B7-1-positive proteinuric kidney disease
.
N Engl J Med
.
2013 Dec 19
;
369
(
25
):
2416
23
.
80.
Delville
M
,
Baye
E
,
Durrbach
A
,
Audard
V
,
Kofman
T
,
Braun
L
, et al.
B7-1 Blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS
.
J Am Soc Nephrol
.
2016 Aug
;
27
(
8
):
2520
7
.
81.
Garin
EH
,
Reiser
J
,
Cara-Fuentes
G
,
Wei
C
,
Matar
D
,
Wang
H
, et al.
Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis
.
Pediatr Nephrol
.
2015 Mar
;
30
(
3
):
469
77
.
82.
Trachtman
H
,
Nelson
P
,
Adler
S
,
Campbell
KN
,
Chaudhuri
A
,
Derebail
VK
, et al.
DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS
.
J Am Soc Nephrol
.
2018
;
29
(
11
):
2745
54
.
83.
Mitwalli
AH
.
Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis?
Nephrol Dial Transplant
.
1998 Jun
;
13
(
6
):
1524
8
.
84.
Feld
SM
,
Figueroa
P
,
Savin
V
,
Nast
CC
,
Sharma
R
,
Sharma
M
, et al.
Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys
.
Am J Kidney Dis
.
1998 Aug
;
32
(
2
):
230
7
.
85.
Muso
E
,
Mune
M
,
Yorioka
N
,
Nishizawa
Y
,
Hirano
T
,
Hattori
M
, et al.
Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS)
.
Clin Nephrol
.
2007 Jun
;
67
(
6
):
341
4
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.